Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A
Division of Psychopharmacology, St Mary's Hospital Center, McGill University, Montreal, Quebec, Canada.
Biol Psychiatry. 1995 Dec 1;38(11):742-6. doi: 10.1016/0006-3223(95)00081-X.
A randomized, placebo-controlled, double-blind, three-way crossover design was used to evaluate the effectiveness of single oral 100 mg doses of CI-988, a cholecystokinin B (CCKB) antagonist, in attenuating panic symptoms induced by intravenous injection of cholecystokinin-tetrapeptide (CCK-4). Thirty healthy men received the following treatments on three separate occasions: placebo capsules/placebo, placebo capsules/CCK-4, or CI-988 capsules/CCK-4. There was no marked difference in the number, time to onset, or duration of panic symptoms between CI-988/CCK-4 and placebo/CCK-4. There was, however, a 14% difference in sum intensity scores between these treatments that was statistically significant (p = 0.039). The symptoms most affected by CI-988 were cold chills/hot flushes, chest pain/discomfort, and anxiety/fear/apprehension. Panic attack frequency also decreased following CI-988 treatment (8/30 vs. 16/30; p = 0.035). This decrease, amid otherwise modest effects, could be explained by a preferential effect of CI-988 on the subjective experience of anxiety/fear/apprehension. Possible reasons for the relatively modest effects of CI-988 on CCK-4-induced panic symptoms are discussed.
采用随机、安慰剂对照、双盲、三向交叉设计，评估单次口服100毫克胆囊收缩素B（CCKB）拮抗剂CI-988对静脉注射胆囊收缩素四肽（CCK-4）诱发的惊恐症状的缓解效果。30名健康男性在三个不同场合接受了以下治疗：安慰剂胶囊/安慰剂、安慰剂胶囊/CCK-4或CI-988胶囊/CCK-4。CI-988/CCK-4组和安慰剂/CCK-4组在惊恐症状的数量、发作时间或持续时间上没有显著差异。然而，这些治疗组之间的总强度得分存在14%的差异，具有统计学意义（p = 0.039）。受CI-988影响最大的症状是寒战/潮热、胸痛/不适以及焦虑/恐惧/担忧。CI-988治疗后惊恐发作频率也有所下降（8/30对16/30；p = 0.035）。在其他影响较小的情况下，这种下降可能是由于CI-988对焦虑/恐惧/担忧主观体验的优先作用。文中讨论了CI-988对CCK-4诱发的惊恐症状影响相对较小的可能原因。
